MBX-2366 (ISG-21) is a potent and specific antimalarial compound with IC50 of 3 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=2 nM) to quantitatively abolish parasite-induced permeability change

KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.

KNX-002 (KNX002) is a potent, specific inhibitor of Toxoplasma gondii class XIV myosin TgMyoA, inhibits TgMyoA ATPase activity with IC50 of 2.8 uM, shows little to no effect on any of the vertebrate myosins.

Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite s

Genz-667348 (Genz667348) is a potent, selective P. falciparum DHODH inhibitor with IC50 of 22, 14 and 42 nM for PfDHODH, PbDHODH and PvDHODH, respectively.

ELQ-331 (ELQ331) is an alkoxycarbonate prodrug of antimalarial compound ELQ-300 (P. falciparum cytochrome bc1 complex inhibitor), shows P. falciparum IC50 of 6 nM.

DSM186 (DSM 186) is a high potent A. baumannii DHODH (AbDHODH) inhibitor with IC50 of 28 nM, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DSM161 (DSM 161) is a high potent A. baumannii DHODH (AbDHODH) inhibitor, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DNDI-6174 is a highly potent inhibitor of Leishmania cytochrome bc1 complex activity, shows broad activity against a panel of representative visceral leishmaniasis clinical isolates from various sources (EC50=10-360 nM).

CWHM-117 is potent nanomolar inhibitor of the Plasmodium aspartic proteases PM-II and PM-IV with IC50 of 4 and 15 nM respectively, exhibits IC50 of 463 nM in the Pf 3D7 infected RBC assays.

AWE402 (AWE-402) is a small molecule inhibitor targeting M. tuberculosis cytochrome bcc-aa3 of the electron transport chain (ETC), shows MIC value of 5 nM activity against Mycobacterium tuberculosis H37Rv.

NSC125044 is a small molecule inhibitor of the influenza virus protein NS1, inhibits different influenza strains cultured in MDCK-UK cells with IC50 of 7-12 uM.

JJ3297 is a potent antagonist of influenza virus non-structural protein 1 (NS1), strongly restores IFN-β mRNA levels and inhibits viral replication in MDCK cells (IC50=0.8 uM).

dEF3122 is a highly potent small molecule inhibitor of influenza virus replication with IC50 of 3 nM in neuraminidase activity assays, taregts NEET family of protein NAF-1.

ANA-0 is a potent inhibitor against the replication of multiple subtypes of influenza A virus, interacts with N-terminal domain of the PA subunit with Kd value of 1.1 uM, and impedes it's endonuclease activity.

VTD227 is a small molecule Vpr-targeting HIV-1 inhibitor, directly binds to Vpr with Kd of 8.8 uM, inhibits HIV-1 replication in monocyte-derived macrophages (MDM) with IC50 of 0.78 uM.

TX-1918 (TX1918) is a specific inhibitor of HIV-1 capsid assembly taregting the C-terminal domain of HIV-1 capsid (CA CTD) with IC50 of 3.81 uM, inhibits viral replication (EC50=15.16 μM) and inhibits CA assembly in vitro.

SO-7g is a novel highly active HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), exhibits moderate to excellent potency against wild-type HIV-1 with EC50 of 5.3 nM.

PAV-206 is a novel potent antiretroviral chemotype that inhibits HIV-1 replication with EC50 of 34 nM in HIV-1-infected MT-2 T cells, and 75 nM in HIV-1-infected peripheral blood mononuclear cells (PBMCs), inhibits HIV-1 replication by interfering with HI

JX-7 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with remarkable inhibitory activity against wild-type HIV-1 (EC50=5 nM) and numerous clinically observed variants in MT-4 cells.

iPAF1C (PAF1C inhibitor) is a first-in-class, specific inhibitor of polymerase-associated factor 1 complex (PAF1C), iPAF1C binds specifically to CTR9 and disrupts of PAF1-CTR9 interaction, enhances HIV-1 latency reversal.

GSK-878 (GSK878) is a highly potent, long-acting inhibitor targeting the HIV-1 capsid with picomolar potency against HIV-1 infection in vitro (EC50=39 pM).

GSK3839919 is a potent, allosteric HIV-1 integrase inhibitor (ALLINI).

GS-9770 is a potent, selective, non-peptidomimetic and orally active HIV protease inhibitor with Ki(app) value of 0.16 nM (recombinant HIV-1 PR).

SAG-524 (SAG524) is a potent and orally bioavailable small molecule inhibitor of HBV replication, reduces HBsAg and HBV-DNA (IC50 = 0.92 nM and 1.4 nM) by destabilizing HBV-RNA.

Neracorvir is a potent anti-HBV agent, targets HBV surface antigen.

E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.

DF-006 is a small molecule, orally active Alpha-kinase 1 (ALPK1) agonist, activates ALPK1 and stimulates host innate immunity locally in liver, DF-006 enacts potent anti-HBV responses in mouse models of HBV and in primary human hepatocytes.

YU385599 is a high-affinity inhibitor of fungal pantothenate kinase (PanK), exhibits excellent activity against the human pathogens Candida albicans, C. glabrata, and C. parapsilosis.

NPD6433 is a novel broad-spectrum antifungal agent with MIC <10 ug/mL against C. albicans, Candida glabrata, Candida auris, and C. neoformans, inhibits Fas1 enoyl reductase activity.